Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Diagnosed with type 2 diabetes mellitus~* HbA1c of 7.1% to 11.0%, inclusive, at screening~* Has stable body weight, i.e., not varying by \>3% for at least 3 months prior to screening~* Fasting plasma glucose concentration \<280 mg/dL (15.5 mmol/L) at screening~* Body mass index of \<45 kg/m2 at screening~* Has been treated with a stable regimen of ≥1500 mg/day metformin for a minimum of 2 months prior to Visit 1 (Screening)~Exclusion Criteria:~* History of pancreatitis or triglycerides \>=500 mg/dL~* Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either~* History of renal transplantation, or is currently receiving renal dialysis, or has an estimated creatinine clearance \<50 mL/min~* Active cardiovascular disease~* Presence or history of severe congestive heart failure~* Central nervous system disease, including epilepsy~* Liver disease~* History of severe gastrointestinal diseases~* Clinically significant malignant disease~* Repeated severe hypoglycemia within the last 6 months~* Any exposure to exenatide (BYETTA® or BYDUREON™) or any GLP-1 analog~* Any DPP-4 inhibitor within 3 months prior screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide once weekly suspension (Type: EXPERIMENTAL): Exenatide once weekly suspension 2mg subcutaneous injection
- Sitagliptin 100mg (Type: ACTIVE_COMPARATOR): Overencapsulated Sitagliptin 100mg oral tablet once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral capsule once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).